Latest Information Update: 19 May 2016
At a glance
- Originator Unknown
- Developer Taisho Pharmaceutical
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Attention-deficit hyperactivity disorder
Most Recent Events
- 09 May 2016 Phase-II clinical trials in Attention-deficit hyperactivity disorder (In children, In adolescents) in Japan (PO) before May 2016 (JapicCTI-163244)